Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
AstraZeneca
Harvard Business School
Moodys
Boehringer Ingelheim

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Patent: 10,233,171

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,233,171
Title:Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
Abstract: The present invention provides, inter alia, a compound having the structure: ##STR00001## Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
Inventor(s): Stockwell; Brent R. (New York, NY), Dixon; Scott J. (New York, NY), Skouta; Rachid (New York, NY)
Assignee:
Application Number:15/442,475
Patent Claims:see list of patent claims

Details for Patent 10,233,171

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novartis Pharms EXTAVIA interferon beta-1b INJECTABLE; SUBCUTANEOUS 125290 001 2009-08-14   Start Trial 2032-04-02 RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial 2032-04-02 RX search
Genentech TNKASE tenecteplase VIAL 103909 001 2000-06-02   Start Trial 2032-04-02 RX search
Ekr Therap RETAVASE reteplase VIAL 103786 001 1998-05-06   Start Trial 2032-04-02 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial 2032-04-02 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial 2032-04-02 RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial 2032-04-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Merck
AstraZeneca
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.